Summary: Ovarian neoplasia comprises a heterogenous group of tumors with distinct clinicopathologic and molecular features and therefore assessment of potential risk factors should be tumor subtype specific. As part of ongoing epidemiological investigations of ovarian neoplasia in Western Australia, we performed an initial review of original pathology reports followed, in selected cases, by reassessment of histology material to optimize accurate diagnosis. Additional immunohistochemistry, often using antibodies unavailable at the time of initial assessment, was also performed as required. From an initial cohort of 1660 cases identified through the Western Australia Cancer Registry, benign, nonepithelial, nonovarian, miscellaneous, and indeterminate cases were excluded. Also excluded were 33 cases that were reclassified as ovarian metastases rather than primary ovarian tumors. Following exclusions there remained 1321 borderline and malignant epithelial neoplasms. The diagnosis was considered accurate in 1186 cases (89.8%) based upon information in the initial pathology reports and clinical follow-up data but uncertain in 135 cases (10.2%). Histologic review was possible in 92 of the latter tumors leading to an amended diagnosis in 63 cases (68.5%). The most common types of diagnostic amendment were the reclassification of high-grade carcinomas of undifferentiated, endometrioid, or transitional appearance as high-grade serous carcinoma, and the reclassification of most carcinomas of mixed epithelial type as ''pure'' carcinomas. This review illustrated specific pitfalls in the diagnosis of ovarian epithelial neoplasia and helped to maintain the accuracy of the Western Australia Cancer Registry. Accurate diagnosis will optimize further epidemiological studies assessing risk factors in specific subtypes of ovarian neoplasia.
neoplasia has been positively linked to certain hereditary factors (BRCA mutations and Lynch syndrome), infertility, pelvic inflammatory disease, and in vitro fertilization, whereas hormonal contraception, parity, and prior salpingectomy or tubal ligation appear to have a protective role (1) (2) (3) (4) (5) (6) .
A limitation of some epidemiological studies of ovarian neoplasia, particularly those conducted more than a decade ago, is that in many cases malignant epithelial tumors were grouped together and regarded as a single entity (epithelial ovarian cancer), and occasionally the same has applied to the analysis of borderline tumors. However, it is now recognized that ovarian tumors comprise a heterogenous group of neoplasms with differing clinical, histologic, immunophenotypic, and molecular characteristics, and hence are likely to have different etiology (7-10). There are 2 major categories of borderline ovarian tumor (serous and mucinous) with a much less common subgroup exhibiting mixed epithelial (seromucinous) differentiation, and there are 5 major subtypes of ovarian carcinoma namely high-grade serous carcinoma (HGSC), low-grade serous carcinoma (LGSC), endometrioid carcinoma (EC), clear cell carcinoma (CCC), and mucinous carcinoma (MUCA). Carcinosarcoma, although less common, is also now regarded as a form of metaplastic carcinoma most often showing high-grade serous differentiation in its epithelial component (9) . HGSC accounts for approximately 65% to 70% of all ovarian carcinomas and hence studies of epithelial ovarian cancer not otherwise specified are heavily biased toward this tumor subtype. This has major implications regarding the investigation of etiological factors, possible preventative measures, and the optimal management of ovarian carcinoma as the identification of risk factors and treatment responses in the less common tumor subtypes may be obscured by the predominance of HGSC (11) .
An additional difficulty presented by epidemiological analysis of relatively uncommon tumors such as ovarian carcinoma is that such studies generally cover a broad time period. This has the benefit of increasing the size of patient cohorts, thus maximizing the power of statistical analysis. However, older histopathology diagnoses may not adhere to currently recognized tumor classifications and may lack the benefit of more recently developed ancillary diagnostic techniques such as immunohistochemistry (IHC) or molecular analysis (12, 13) . Furthermore, there may be significant changes in the interpretation of specific diagnostic scenarios; for example, the appreciation that many tumors previously classified as high-stage ovarian MUCA are likely to represent primary nongynecologic malignancies metastatic to the ovary (14, 15) .
In a previous population-based study performed in Western Australia (WA), we found that women who had undergone hysterectomy with or without unilateral salpingo-oophorectomy had a reduced risk of ovarian cancer, confirming earlier reports (3). Unexpectedly, however, patients who had undergone unilateral salpingo-oophorectomy without hysterectomy had a 4-fold increased risk of ovarian cancer. This study has since been extended to include a larger cohort of approximately 850,000 women in WA followed up for up to 45 years. Their detailed demographic, reproductive, and surgical data obtained through linkage of routinely collected hospital, births, and cancer registry information will be used to further clarify risk factors associated with the development of borderline or malignant epithelial ovarian neoplasms. However, in view of the potential limitations in tumor classification discussed above, it was considered beneficial that pathology review should be performed for identified cases, comprising at a minimum evaluation of the original diagnostic reports with reexamination of the original histologic material if required. In this report we discuss the results of this pathologic review, discussing amendments to the original diagnoses, and the effects such review might have on epidemiological analysis.
MATERIALS AND METHODS
The study group comprised all women born in WA between 1945 and 1975 recorded in the Western Australia Cancer Registry (WACR) to have a new diagnosis of borderline or malignant ovarian tumor between January 1982 and the end of June 2014. Given the heterogeneity of ovarian neoplasia one important aspect of this study was to ensure, as far as possible, that the tumors were correctly assigned in terms of pathologic diagnosis. Therefore, the pathology reports of the ovarian tumors (and those of any relevant earlier or subsequent cytology, biopsy, or resection specimens) were reviewed by a gynecologic pathologist (C.J.R.S.). In some cases, clinical followup data were used to aid diagnostic categorization. For example, in cases of MUCA, long-term patient survival and the absence of any subsequently identified extraovarian mucinous neoplasm were considered strong support for the primary nature of the ovarian tumor. Cases in which the pathology report was unavailable were excluded. For the remaining cases, based upon the clinical information, the microscopic description of the tumor, the results of any IHC and molecular analysis, and available follow-up data, the original diagnosis was determined to be either confirmed or uncertain. The latter category included specific diagnostic scenarios (outlined below) that are known to cause difficulty in the diagnosis or subtyping of ovarian neoplasia. Review of the original histologic and/or cytologic slides was performed in these cases. If review of tumors with uncertain diagnosis was impossible then the cases were excluded. Additional IHC was performed in selected cases, often using antibodies that were not available at the time of initial diagnosis. In the histologically reviewed (uncertain) cases, it was determined whether the original diagnosis was confirmed or amended, and the contribution of any additional IHC was also evaluated.
The indications for histologic review included the following: tumors initially reported as ''papillary adenocarcinoma'' or carcinoma/adenocarcinoma, not otherwise specified; bilateral tumors other than those of serous type; tumors in which there was earlier or subsequent identification of an extraovarian neoplasm that may have been confused with a primary ovarian tumor (particularly mucinous and endometrioid carcinoma); all cases reported as grade 3 EC, primary transitional cell carcinoma, or carcinoma of mixed histologic type; cases in which there appeared to be a possible discrepancy between the microscopic description of the tumor, the results (or absence) of appropriate ancillary studies, and/or clinical follow-up information.
During the study period some serous carcinomas had been reported initially as moderately differentiated/grade 2, based upon the ''universal'' grading system for ovarian neoplasia (16) It is now accepted that HGSC and LGSC are different entities rather than different grades of 1 tumor type and thus the intermediate-grade category for serous carcinoma is no longer applicable (17) . In the current review, it was clear from the original pathology reports that most serous carcinomas initially reported to be grade 2 were HGSC and these were reclassified as such. However, cases in which the distinction of HGSC and LGSC was impossible were reviewed.
The current pathologic review concentrated on the major subtypes of borderline and malignant epithelial tumors as these are the main focus of ongoing epidemiological investigations. Therefore, sex cordstromal neoplasms, malignant germ cell tumors, and other rare miscellaneous tumors were not examined in detail. However, cases with possible discordant diagnoses were reviewed whenever possible following the guidelines above. Furthermore, many of the tumors in these categories (particularly sex cordstromal tumors) have been reviewed during recent unrelated studies (18) (19) (20) .
The study received ethics approval (WA Department of Health HREC #2015/07, Curtin University HREC HR 41/2015).
RESULTS
In total, 1660 women were identified from the WACR database during the study period. The original pathology reports were unavailable in 42 cases and 2 spurious cases were identified (one a duplicated entry and the other a non-WA case that was reviewed as part of an independent study); these were excluded from further analysis. There were 84 malignant sex cord-stromal tumors, 56 malignant germ cell tumors, and 25 miscellaneous rare neoplasms. Of the remaining 1451 cases, 24 were considered to be benign and 33 were favored to represent metastases to the ovary following reassessment. Twenty-one tumors remained of indeterminate subtype or origin usually because of limited diagnostic material. Fifty-two cases were excluded as they did not represent primary ovarian neoplasms. These included pathologically unrelated tumors such as retroperitoneal sarcomas that were captured in the initial search due to overlapping codes with ovarian neoplasia in the WACR. The process of case review and exclusion is outlined in Figure 1 . Histologic and/or cytologic review was performed in 28 of the excluded tumors leading to a revision of the original diagnosis in 23 cases (82.1%), most commonly resulting in a final diagnosis of metastatic carcinoma rather than a primary ovarian carcinoma (n = 14, Table 1 ). In the latter cases the tumor origin was favored to be from the gastrointestinal tract, cervix, and endometrium in 9, 3, and 2 cases, respectively, and the amended diagnoses were supported by additional IHC studies in 10 cases (Figs. 2, 3) . Following the selection process described above, 1321 borderline and malignant epithelial tumors of major subtypes remained in the main study group (Fig. 1) . The initial diagnosis was considered to be accurate in 1186 (89.8%) cases based upon the information presented in the original pathology report together with any relevant follow-up data. However, the diagnosis was considered uncertain in the remaining 135 (10.2%) cases almost all of which (n = 129) were malignant. Slide review was performed in 92 (68.1%) of the uncertain tumors but was impossible in the remaining 43 (31.9%) cases because the original diagnostic slides were unavailable for examination. Following exclusion of the latter cases, there remained 1278 tumors including 419 borderline tumors and 859 carcinomas. The number of cases with histologic review, the number with amended diagnosis, and the use of additional IHC for each tumor subtype are summarized in Table 2 .
Of the 92 uncertain cases that underwent histologic review, the original diagnosis was confirmed in 29 (31.5%) cases but was amended in the remaining 63 (68.5%) cases. The types of diagnostic amendment are summarized in Table 3 . Across the histologic spectrum, the most common causes of diagnostic amendment were changes in grade (arguably tumor subtype rather than grade in serous carcinomas), tumor categorization (eg, grade 3 EC being revised to HGSC), and reclassification of cases initially reported to be carcinomas of mixed histologic type. Only 2 of the latter cases in this study were confirmed upon review, both of which showed endometrioid and clear cell components. In the present analysis these were categorized according to their dominant component (1 case each of CCC and EC). In contrast, 14 carcinomas initially reported to be of mixed histologic type were considered to be ''pure'' carcinomas, most often HGSC, with variable morphology following review (Table 3 and Figs. 4, 5).
DISCUSSION
Population-based epidemiological studies can identify factors that may increase or decrease the risks of developing specific types of tumor but analysis is complicated in ovarian neoplasia which encompasses a range of tumor subtypes most of which have distinct clinicopathologic features (7, 8) . Furthermore, there is evidence that risk factor associations vary according to the histologic subtype of ovarian neoplasia (13) . For example, cigarette smoking has been linked to an increased risk of borderline and malignant ovarian mucinous tumors, whereas salpingectomy or fallopian tube sterilization procedures seem to be protective toward the development of ovarian EC and CCC, both of which are associated with endometriosis (21-23). Bilateral salpingectomy or salpingo-oophorectomy is also protective against HGSC with most such tumors now considered to arise within the fallopian tube (10). It is, therefore, important that any assessment of risk factors in ovarian neoplasia is subtype specific, and this in turn necessitates accurate histologic diagnosis. In the present study we have evaluated pathologic review as part of this process in a large series of tumors initially categorized as borderline or malignant ovarian neoplasms identified through the WACR.
It is acknowledged that the present pathology review has several limitations. Firstly, a proportion of cases had to be excluded as the initial diagnostic reports could not be accessed, slides were unavailable for review, or because the final diagnosis remained uncertain. We also accept that histologic review was performed in very few borderline tumors and it is likely that at least some cases would now be classified as benign neoplasms with focal proliferative changes, based upon the limited extent and mild nature of the atypia (24) . Most significantly, in the great majority of cases (approximately 90%), acceptance of the final diagnosis was based only upon review of the pathology reports, albeit supported by clinical follow-up data and subsequent biopsy findings in many cases. Arguably, the ''gold standard'' for pathologic assessment would comprise complete histologic review of all tumors, ideally by a panel of pathologists. However, this would be impractical given the number of cases in studies such as this, and it would also be impossible to review those tumors (mainly from the earlier part of the study period) in which the original histologic material was no longer available. Despite these restrictions, we believe this has been a valuable review process and might serve as a practical approach for similar large epidemiological studies of neoplasia where complete pathologic reassessment of all cases is not feasible. The selective histologic review in this study, with reexamination of original slides being prompted by an assessed likelihood of diagnostic error, was supported by the high proportion of amended diagnoses (82% of the reviewed excluded cases and 69% of the reviewed reclassified cases). For example, 33 metastatic tumors were identified most of which had been initially interpreted to be primary ovarian mucinous or endometrioid adenocarcinomas. The histologic difficulty posed by ovarian metastases has been well documented, and the judicious use of IHC in this setting has also been emphasized (14, 15) . In the current series IHC was helpful in confirming the metastatic origin of 7 colorectal tumors (including 1 low-grade appendiceal mucinous neoplasm) and the cervical origin of 3 tumors. Two of the latter occurred in patients with previously treated cervical adenocarcinomas but nonetheless the ovarian tumors were initially interpreted to be independent primary ovarian ECs. These cases presented before recent studies that have highlighted the histologic features of cervical adenocarcinoma metastatic to the ovary (25) (26) (27) , and the correct cell change, respectively. As in the case of metastatic neoplasms, this reassessment was often supported by IHC analysis, using the characteristic differential staining patterns of such tumors with WT1, p53, p16, HNF1, napsin A, ARID1A, and estrogen receptor (28) . Our findings support recent suggestions that genuine mixed epithelial tumors of the ovary are rare (9, 10, 29, 30) .
We also found that many tumors that were initially reported to be undifferentiated carcinomas, or highgrade carcinomas of uncertain origin (primary vs. metastatic), were reclassified as HGSC. Likewise, although few tumors in this series had an initial diagnosis of grade 3 EC or transitional cell carcinoma, most were reclassified as HGSC upon review with the initial diagnosis being confirmed in only 2/6 and 1/4 cases, respectively. As noted above, the distinction of endometrioid and serous carcinoma can be problematic when the latter exhibits a predominant glandular rather than papillary architecture, but immunophenotypic and molecular data demonstrate the serous nature of the majority of these cases (9, 10, 29, 30) . Our findings support the recent study by Lim et al. (31) suggesting that ovarian grade 3 EC is uncommon, and that many cases previously categorized as such are in fact HGSC. Regarding the consequences of tumor reclassification, it is also noteworthy that the solid (undifferentiated), endometrioid-like, and transitional-like morphologic patterns in HGSC are associated with BRCA1 mutations, whether of germline or somatic origin, with potential implications regarding hereditary predisposition and therapeutic response (32, 33) .
In summary, we describe the results of pathology report assessment and selective histopathologic review in a population-based series of >1500 ovarian tumors identified through a Cancer Registry. The review illustrated specific areas of diagnostic uncertainty, many of which led to case exclusion or to amended diagnosis, thus helping to maintain the accuracy and the utility of the Registry data. We believe this type of review is practical, and the methods could be applied in similar large-scale epidemiological studies to ensure that risk factor assessment in neoplasia is based upon accurate tumor subtyping.
